• Radiation Oncology Journal
• /
• 제32권4호
• /
• pp.262-265
• /
• 2014

Tamoxifen and radiotherapy are used in breast cancer treatment worldwide. Radiation recall dermatitis (RRD), induced by tamoxifen, has been rarely reported. Herein, we report a RRD case induced by tamoxifen. A 47-year-old woman had a right quadrantectomy and an axillary lymph node dissection due to breast cancer. The tumor was staged pT2N0; it was hormone receptor positive, and human epidermal growth factor receptor 2 negative. The patient received adjuvant chemotherapy followed by tamoxifen and radiotherapy. After 22 months of tamoxifen, the patient developed a localized heating sensation, tenderness, edema, and redness at the irradiated area of the right breast. The symptoms improved within 1 week without treatment. Three weeks later, however, the patient developed similar symptoms in the same area of the breast. She continued tamoxifen before and during dermatitis, and symptoms resolved within 1 week.

• Radiation Oncology Journal
• /
• 제32권3호
• /
• pp.156-162
• /
• 2014

Purpose: This study was designed to evaluate the efficacy and safety of topically applied recombinant human epidermal growth factor (rhEGF) for the prevention of radiation-induced dermatitis in cancer patients. Materials and Methods: From December 2010 to April 2012, a total of 1,172 cancer patients who received radiotherapy (RT) of more than 50 Gy were prospectively enrolled and treated with EGF-based cream. An acute skin reaction classified according to the Radiation Therapy Oncology Group 6-point rating scale was the primary end point and we also assessed the occurrence of edema, dry skin, or pruritus. Results: The percentage of radiation dermatitis with maximum grade 0 and grade 1 was 19% and 58% at the time of 50 Gy, and it became 29% and 47% after completion of planned RT. This increment was observed only in breast cancer patients (from 18%/62% to 32%/49%). Adverse events related to the EGF-based cream developed in 49 patients (4%) with mild erythema the most common. Skin toxicity grade >2 was observed in 5% of the patients. Edema, dry skin, and pruritus grade ${\geq}3$ developed in 9%, 9%, and 1% of the patients, respectively. Conclusion: Prophylactic use of an EGF-based cream is effective in preventing radiation dermatitis with tolerable toxicity. Further studies comparing EGF cream with other topical agents may be necessary.

• 생명과학회지
• /
• 제31권4호
• /
• pp.418-424
• /
• 2021

자외선과 병원미생물 감염 등으로 야기되는 다양한 피부조직의 손상은 피부염증을 일으킨다. 피부염 치료제로 염증을 완화시키는 항히스타민 또는 스테로이드 계열 약물이 처방되고 있다. 하지만 부적절한 스테로이드 복용은 피부 장벽 약화나 골다공증 등의 부작용을 초래할 수 있어, 부작용이 적은 피부염 치료 약물은 임상적으로 중요하다. 콜레스테롤 합성에 필요한 3-hydroxy-3-methylglutaryl-coenzyme A 환원효소를 억제하는 statin은 혈청 콜레스테롤 수준을 낮추는 약물로 고지혈증이나 심혈관질환에 널리 처방되고 있다. 이러한 콜레스테롤 생성 억제 기능에 더하여, 흥미롭게도, statin 약물은 골관절염과 관련된 여러 연구에서 항염증 효과가 있는 것으로 보고되고 있다. 본 연구에서는 피부 장벽의 주요 구성 세포인 각질형성세포(HaCaT 세포주)에서 atorvastatin 및 fluvastatin의 잠재적인 항염증 효과를 조사하였다. IL-1β 자극에 반응하여 HaCaT 세포에서 염증반응의 주요한 인자인 COX2 단백질의 발현이 증가하였다. 이러한 COX2 단백질의 발현 증가는 atorvastatin 또는 fluvastatin 약물 처리로 억제되었다. 비슷하게, IL-1β에 의해 발현이 증가된 다른 염증반응 유전자(iNOS 그리고MMP-1 등)의 발현양도 atorvastatin 또는 fluvastatin 약물 처리로 감소되었다. 종합하면, 본 연구결과는 HaCaT 세포에서 IL-1β 로 유도된 염증반응이 atorvastatin 및 fluvastatin 약물 처리로 하향 조절될 수 있음을 보여준다. 따라서, 본 연구결과는 atorvastatin 및 fluvastatin 약물이 피부염증을 완화시키는 조절제로 응용될 수 있다는 것을 제시한다.